SCHEMBL435024

SCHEMBL435024

Cc1ccc2c(c1)C(=O)N(C(C)(C)C)C2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.45
HTR2A P28223 2/20 0.43
HTR2C P28335 2/20 0.43
HTR2B P41595 2/20 0.43
METAP1 P53582 3/20 0.41
PARP1 P09874 2/20 0.40
PARP10 Q53GL7 2/20 0.40
NPC1 O15118 1/20 0.38
PKM P14618 1/20 0.38
RAB9A P51151 1/20 0.38
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
HSD17B10 Q99714 1/20 0.36
AADAT Q8N5Z0 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
ELANE P08246 1/20 0.35
TYMS P04818 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31069561 0.83 CYP2A6 (0.38) ACHEHTR2AHTR2CHTR2BNPC1
SCHEMBL22151641 0.81 HTR2C (0.43) HTR2AHTR2CHTR2BMETAP1PARP1
SCHEMBL21101461 0.81 ALDH1A1 (0.42) HTR2AHTR2CHTR2BNPC1RAB9A
SCHEMBL18793920 0.81 MEN1 (0.41) METAP1PARP1PARP10MEN1KMT2A
SCHEMBL435023 0.77 DDB1 (0.48) ACHEHTR2AHTR2CHTR2BMETAP1
SCHEMBL122427 0.77 KMT2A (0.57) ACHEHTR2AHTR2CHTR2BNPC1
SCHEMBL9266150 0.76 MEN1 (0.47) HSD17B10MEN1KMT2AALDH1A1GAA
SCHEMBL22454239 0.75 METAP1 (0.43) ACHEHTR2AHTR2CHTR2BMETAP1
SCHEMBL31069539 0.75 CYP3A4 (0.36) NPC1PKMRAB9AHSD17B10MEN1
SCHEMBL29338553 0.74 PIK3CA (0.47) ACHEHTR2AHTR2CHTR2BSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9206173-B2 Heterocyclic compounds for the treatment of stress-related conditions OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2015-12-08 US disclosed
US-9206173-B2 Heterocyclic compounds for the treatment of stress-related conditions OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2015-12-08 US disclosed
US-20120065189-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-03-15 US disclosed
US-20120065189-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065189-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS NR3C1, NR3C2, CRH ACHE 2940/4885HTR2A 272/4885HTR2C 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.